Heart Failure’s Plumbing Myth: Why Stents Can’t Outrun Modern Meds

Key Takeaway: A groundbreaking consensus statement from European experts concludes that for most patients with heart failure with reduced ejection fraction (HFrEF), procedures to open blocked heart arteries offer no improvement beyond the benefits already provided by today’s powerful medications. Revascularization should be primarily reserved for patients whose chest pain persists despite fully optimized medical therapy. This represents a significant shift away from reflexive interventional approaches.

The End of an Instinct

For decades, the logic seemed irrefutable: If a heart is failing and its arteries are blocked, open them up. Restore blood flow, salvage the oxygen-starved muscle, and bring the patient back to life. This reasoning led to countless catheterizations, stent placements, and bypass surgeries in patients with heart failure and coronary artery disease. But a major new expert consensus report, published in the European Journal of Heart Failure, directly confronts this instinct, declaring that in the modern medical era, revascularization has shown no benefit for patients with heart failure with reduced ejection fraction^[1]. The statement is a sobering recalibration and carries a reassuring message for patients: The medications you’re taking may be more powerful than the procedures you’ve been told you need.

What Did the Experts Conclude?

This is not a single clinical trial, but rather an expert consensus statement synthesized by leading European heart failure and interventional cardiology specialists reviewing the totality of available evidence. Their conclusions are notable for their clarity. First, in the context of modern guideline-directed medical therapy (GDMT), revascularization has not been shown to benefit survival or heart failure outcomes in stable HFrEF patients. Second, the decision to pursue any revascularization procedure should be made collaboratively by a multidisciplinary “heart team,” as the evidence is limited and at times conflicting. Third, the once-popular strategies of using viability testing or ischemia imaging to select patients for revascularization are now considered controversial, as they lack the robust clinical trial support many had assumed. Finally, the consensus document narrows the primary indication for revascularization to a specific clinical scenario: persistent, refractory angina—that is, chest pain caused by diminished blood flow—that continues despite optimal medical and device therapy.

Why Modern Medications Changed the Equation

To understand why this shift is so significant, it’s essential to appreciate just how dramatically heart failure pharmacotherapy has evolved. A generation ago, the medical toolkit for HFrEF was limited to diuretics, digoxin, and early ACE inhibitors. Landmark trials in the 1990s and 2000s established beta-blockers and mineralocorticoid receptor antagonists as cornerstones of therapy, each independently shown to reduce mortality^[2]. But the true revolution came in the last decade with two classes of drugs that have fundamentally altered the course of heart failure.

Angiotensin receptor-neprilysin inhibitors (ARNIs), exemplified by sacubitril/valsartan, demonstrated a stunning reduction in cardiovascular death and heart failure hospitalizations compared to the previous gold-standard ACE inhibitor enalapril in the PARADIGM-HF trial^[3]. Then came the sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes, which delivered remarkable benefits in heart failure patients irrespective of their diabetes status. The DAPA-HF trial showed that dapagliflozin reduced the composite risk of worsening heart failure or cardiovascular death in patients with HFrEF^[4].

Together, these four pillars of modern GDMT—ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors—form such a powerful pharmacological foundation that the incremental benefit of mechanically restoring coronary blood flow appears to be negligible for most patients. A failing heart, it turns out, is not just a “plumbing” problem. Its dysfunction involves complex processes like neurohormonal activation, inflammatory cascades, adverse cardiac remodeling, and metabolic disturbances, which medications now target with remarkable precision.

This understanding also explains why viability-based strategies have fallen out of favor. The STICH trial, which randomized patients with ischemic cardiomyopathy to coronary artery bypass grafting plus medical therapy versus medical therapy alone, did not initially show a significant overall survival benefit for surgery at its primary endpoint^[5]. While a modest advantage for surgery was suggested with longer-term follow-up, this study was conducted before the widespread use of ARNIs and SGLT2 inhibitors. A substudy examining myocardial viability found that the presence of living heart muscle did not reliably identify patients who benefited from surgery^[6]. The new consensus report directly acknowledges this uncertainty.

The Oculostenotic Reflex

Cardiologists have long spoken, sometimes ruefully, of the “oculostenotic reflex”—the almost involuntary urge to fix a blockage simply because one is seen on an angiogram. When a catheterization reveals a 90% stenosis in a major coronary artery, the pressure to intervene—from both clinical training and patient expectation—is immense. This consensus document argues firmly against that reflex. It asks clinicians to distinguish between two fundamentally different questions: Is this vessel blocked? And: Is this blockage causing the patient’s symptoms? For a patient whose primary complaint is shortness of breath from a weakened heart muscle, rather than exertional chest pain, that blockage may be an incidental finding—anatomically real, but clinically irrelevant to the patient’s dominant problem.

What This Means for Patients

For the millions of people living with heart failure and coronary artery disease, this consensus document holds several practical implications. If you have been diagnosed with HFrEF, the most critical step is to ensure you are on fully optimized GDMT—all four foundational medications titrated to target doses as tolerated. This is the foundation that modern evidence most strongly supports. If your primary symptoms are shortness of breath, fatigue, and fluid retention, rather than chest pain, a procedure to open blocked arteries is unlikely to improve your condition. If you have persistent chest pain despite optimal medical therapy and appropriate device therapies like a defibrillator or cardiac resynchronization, then revascularization becomes a reasonable option—but one that should be discussed within a multidisciplinary heart team, not decided reflexively in the catheterization lab.

Important Limitations

This document is a consensus statement, not a randomized controlled trial. It reflects the best collective judgment of experts interpreting a body of evidence that is, by their own admission, limited and sometimes contradictory. Many of the major trials that shaped these conclusions were conducted before the full adoption of modern quadruple GDMT, meaning we lack definitive data on revascularization outcomes in patients already taking ARNIs and SGLT2 inhibitors. New, well-designed randomized controlled trials involving patients on modern therapies are critically needed. Until that data arrives, this consensus provides the most authoritative framework available—one that recenters medications as the cornerstone of therapy while reserving invasive procedures for a clearly defined, symptom-driven indication.

Scientific Sources

1. Haring B, et al. Revascularization of coronary artery disease in heart failure. A European Journal of Heart Failure Expert Consensus Statement. European journal of heart failure. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42496134/
2. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999. DOI: 10.1056/NEJM199909023411001
3. McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014. DOI: 10.1056/NEJMoa1409077
4. McMurray JJ, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. DOI: 10.1056/NEJMoa1911303
5. Velazquez EJ, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011. DOI: 10.1056/NEJMoa1100356
6. Bonow RO, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011. DOI: 10.1056/NEJMoa1100358